nanoparticle manufacturing technology with sophisticated physical chemistry techniques and biological investigations using the skills and scientific expertise of a group of third-party, reputable scientists and entrepreneurs to collaborate with Sona’s team. This initiative will support the biocompatibility of Sona’s patented gold nanorod production techniques and serve as a platform for future research projects aimed at finding the most promising medicinal uses for Sona’s technology.
Dr. Warren Chan, University of Toronto’s Director of the Institute of Bioengineering, expressed hopes over the collaboration and future nano research. He said, “The biocompatibility of nanomaterials will be an important component to the unlocking of new, potentially life-saving, medical nanotechnology applications and so our study will explore Sona Nanotech’s gold nanorods as a safe, non-toxic material for use ‘in-vivo’.”
Darren Rowles, president and Chief Scientific Officer of Sona Nanotech, expressed delight over the partnership. He said, “We are delighted to be working with Dr. Chan, one of the most important nanotechnology scientists in the world, and we are excited to explore with him the unique attributes and benefits our technology may bring to enabling new, important biomedical applications.”
